R1 RCM Inc (NASDAQ:RCM) Receives $14.25 Consensus Target Price from Analysts

Share on StockTwits

R1 RCM Inc (NASDAQ:RCM) has been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $13.40.

A number of research analysts have recently weighed in on RCM shares. ValuEngine downgraded shares of R1 RCM from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Zacks Investment Research upgraded shares of R1 RCM from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Wednesday. Robert W. Baird set a $14.00 price target on shares of R1 RCM and gave the company a “buy” rating in a report on Thursday, September 12th. Finally, BidaskClub downgraded shares of R1 RCM from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st.

Shares of NASDAQ:RCM traded up $0.31 during trading on Friday, reaching $9.51. 51,757 shares of the company traded hands, compared to its average volume of 1,297,998. The firm has a fifty day simple moving average of $10.48 and a 200 day simple moving average of $11.37. The firm has a market cap of $1.05 billion, a P/E ratio of -29.59 and a beta of 0.10. R1 RCM has a 1-year low of $7.10 and a 1-year high of $13.19. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 106.30.

R1 RCM (NASDAQ:RCM) last issued its earnings results on Tuesday, August 6th. The financial services provider reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). The company had revenue of $295.00 million for the quarter, compared to analyst estimates of $294.11 million. R1 RCM had a negative net margin of 2.22% and a negative return on equity of 249.01%. The company’s quarterly revenue was up 41.9% on a year-over-year basis. During the same period last year, the business earned ($0.07) EPS. As a group, research analysts anticipate that R1 RCM will post 0.06 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in R1 RCM by 414.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,116,648 shares of the financial services provider’s stock worth $26,627,000 after acquiring an additional 1,705,447 shares during the period. Citadel Advisors LLC raised its holdings in R1 RCM by 1,112.7% in the 2nd quarter. Citadel Advisors LLC now owns 724,997 shares of the financial services provider’s stock worth $9,120,000 after acquiring an additional 665,215 shares during the period. SG Americas Securities LLC raised its holdings in R1 RCM by 4,379.7% in the 2nd quarter. SG Americas Securities LLC now owns 656,772 shares of the financial services provider’s stock worth $8,262,000 after acquiring an additional 642,111 shares during the period. Nuveen Asset Management LLC bought a new position in R1 RCM in the 2nd quarter worth $7,505,000. Finally, RK Capital Management LLC bought a new position in R1 RCM in the 2nd quarter worth $5,712,000. Institutional investors and hedge funds own 70.75% of the company’s stock.

About R1 RCM

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

See Also: The Structure of a Futures Contract

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.